Editorial: Pharmacogenetics and mental disease.
D000107:Acetylation; D000759:Adjuvants, Anesthesia / Q000009:adverse effects; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects; D001289:Attention Deficit Disorder with Hyperactivity; D001711:Biotransformation; D002648:Child; D003863:Depression / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D005955:Glucosephosphate Dehydrogenase Deficiency; D006801:Humans; D007223:Infant; D008099:Liver / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D009661:Nortriptyline / Q000009:adverse effects; D010597:Pharmacogenetics; D012559:Schizophrenia / Q000188:drug therapy; D019966:Substance-Related Disorders; D013390:Succinylcholine / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000009:adverse effects
D000759:Adjuvants, Anesthesia; D000927:Anticonvulsants; D000928:Antidepressive Agents; D014149:Tranquilizing Agents; D009661:Nortriptyline; D013390:Succinylcholine